![](/img/cover-not-exists.png)
Treatment with lenalidomide does not appear to increase the risk of progression in lower risk myelodysplastic syndromes with 5q deletion. A comparative analysis by the Groupe Francophone des Myelodysplasies
Ades, L., Le Bras, F., Sebert, M., Kelaidi, C., Lamy, T., Dreyfus, F., Eclache, V., Delaunay, J., Bouscary, D., Visanica, S., Turlure, P., Bresler, A. G., Cabrol, M.-P., Banos, A., Blanc, M., Vey, N.,Volume:
97
Language:
english
Journal:
Haematologica
DOI:
10.3324/haematol.2011.045914
Date:
February, 2012
File:
PDF, 269 KB
english, 2012